MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
Author:
Publisher
Elsevier BV
Subject
Pharmacology,Immunology,Immunology and Allergy
Reference37 articles.
1. Targeted therapy for metastatic renal cell carcinoma;Patel;Br J Cancer,2006
2. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007
3. The von Hippel–Lindau tumor suppressor protein and clear cell renal carcinoma;Kaelin;Clin Cancer Res,2007
4. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor;Roskoski;Biochem Biophys Res Commun,2007
5. Molecular basis for sunitinib efficacy and future clinical development;Faivre;Nat Rev Drug Discov,2007
Cited by 240 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration;JCI Insight;2024-01-09
2. Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma;Cancer Drug Resistance;2023-12-28
3. Effect of sunitinib against Echinococcus multilocularis through inhibition of VEGFA-induced angiogenesis;Parasites & Vectors;2023-11-07
4. The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma;BMC Cancer;2023-10-30
5. Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics;British Journal of Pharmacology;2023-10-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3